David Knopman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5527354/publications.pdf

Version: 2024-02-01

634	82,252	807	547
papers	citations	118 h-index	264 g-index

649	649	649	51448
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 263-269.	0.4	12,681
2	Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron, 2011, 72, 245-256.	3.8	4,176
3	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 2011, 134, 2456-2477.	3.7	3,913
4	Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology, The, 2010, 9, 119-128.	4.9	3,792
5	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurology, The, 2013, 12, 207-216.	4.9	3,378
6	Introduction to the recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 257-262.	0.4	1,547
7	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 2016, 87, 539-547.	1.5	1,216
8	Mild Cognitive Impairment. Archives of Neurology, 2009, 66, 1447-55.	4.9	1,160
9	Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica, 2014, 128, 755-766.	3.9	1,060
10	Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain, 2009, 132, 1355-1365.	3.7	975
11	11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain, 2008, 131, 665-680.	3.7	819
12	Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology, 2001, 56, 42-48.	1.5	793
13	Alzheimer disease. Nature Reviews Disease Primers, 2021, 7, 33.	18.1	784
14	A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease. New England Journal of Medicine, 1992, 327, 1253-1259.	13.9	627
15	Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain, 2006, 129, 1385-1398.	3.7	624
16	The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics. Neuroepidemiology, 2008, 30, 58-69.	1.1	623
17	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 205-216.	0.4	581
18	Neuropathologic Features of Amnestic Mild Cognitive Impairment. Archives of Neurology, 2006, 63, 665.	4.9	562

#	Article	IF	Citations
19	Association of Mediterranean Diet with Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2014, 39, 271-282.	1.2	540
20	An operational approach to National Institute on Agingâ€“Alzheimer's Association criteria for preclinical Alzheimer disease. Annals of Neurology, 2012, 71, 765-775.	2.8	520
21	Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs. Alzheimer Disease and Associated Disorders, 1997, 11, 13-21.	0.6	518
22	Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nature Communications, 2018, 9, 2098.	5.8	484
23	Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. Hypertension, 2016, 68, e67-e94.	1.3	482
24	Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 710-717.	0.4	461
25	Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition. JAMA - Journal of the American Medical Association, 2017, 317, 1443.	3.8	451
26	Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. JAMA Neurology, 2017, 74, 1246.	4.5	404
27	Cascading network failure across the Alzheimerâ€™s disease spectrum. Brain, 2016, 139, 547-562.	3.7	401
28	Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimer's and Dementia, 2011, 7, 80-93.	0.4	399
29	Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies. NeuroImage, 2008, 39, 1186-1197.	2.1	391
30	An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathologica Communications, 2016, 4, 58.	2.4	388
31	Plasma phosphoâ€tau181 increases with Alzheimer's disease clinical severity and is associated with tauâ€• and amyloidâ€positron emission tomography. Alzheimer's and Dementia, 2018, 14, 989-997.	0.4	386
32	DLB fluctuations. Neurology, 2004, 62, 181-187.	1.5	383
33	Non-Stationarity in the â€œResting Brainâ€™sâ€•Modular Architecture. PLoS ONE, 2012, 7, e39731.	1.1	382
34	Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia. Archives of Neurology, 2006, 63, 674.	4.9	377
35	Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology, 2014, 82, 317-325.	1.5	361
36	Midlife Hypertension and 20-Year Cognitive Change. JAMA Neurology, 2014, 71, 1218.	4.5	358

#	Article	IF	Citations
37	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain, 2012, 135, 794-806.	3.7	355
38	Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurology, The, 2012, 11, 868-877.	4.9	355
39	Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain, 2008, 131, 2957-2968.	3.7	354
40	Long-term tacrine (Cognex) treatment. Neurology, 1996, 47, 166-177.	1.5	340
41	TDP-43 is a key player in the clinical features associated with Alzheimerâ€™s disease. Acta Neuropathologica, 2014, 127, 811-824.	3.9	336
42	Brain Î²-amyloid load approaches a plateau. Neurology, 2013, 80, 890-896.	1.5	335
43	Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimer's and Dementia, 2021, 17, 696-701.	0.4	330
44	TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinsonâ€™s disease. Molecular Neurodegeneration, 2013, 8, 19.	4.4	323
45	Age, Sex, andAPOEÎµ4 Effects on Memory, Brain Structure, and Î²-Amyloid Across the Adult Life Span. JAMA Neurology, 2015, 72, 511.	4.5	305
46	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302
47	Age-specific population frequencies of cerebral Î²-amyloidosis and neurodegeneration among people with normal cognitive function aged 50â€“89 years: a cross-sectional study. Lancet Neurology, The, 2014, 13, 997-1005.	4.9	297
48	Association Between Olfactory Dysfunction and Amnestic Mild Cognitive Impairment and Alzheimer Disease Dementia. JAMA Neurology, 2016, 73, 93.	4.5	294
49	MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology, 2003, 60, 253-260.	1.5	279
50	Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain, 2009, 132, 2932-2946.	3.7	277
51	Clinicopathologic and¹¹C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimerâ€™s disease spectrum. Brain, 2015, 138, 1370-1381.	3.7	270
52	Validation of the Telephone Interview for Cognitive Status-modified in Subjects with Normal Cognition, Mild Cognitive Impairment, or Dementia. Neuroepidemiology, 2010, 34, 34-42.	1.1	245
53	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurology, The, 2014, 13, 676-685.	4.9	245
54	Age-specific and sex-specific prevalence of cerebral Î²-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50â€“95 years: a cross-sectional study. Lancet Neurology, The, 2017, 16, 435-444.	4.9	241

#	Article	IF	Citations
55	Version 3 of the National Alzheimerâ€™s Coordinating Centerâ€™s Uniform Data Set. Alzheimer Disease and Associated Disorders, 2018, 32, 351-358.	0.6	241
56	Correlates of Cognitive Function in Middle-Aged Adults. Gerontology, 1998, 44, 95-105.	1.4	237
57	Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology, 2011, 77, 875-882.	1.5	233
58	Suspected non-Alzheimer disease pathophysiology â€” concept and controversy. Nature Reviews Neurology, 2016, 12, 117-124.	4.9	230
59	Mild Cognitive Impairment and Mild Dementia: A Clinical Perspective. Mayo Clinic Proceedings, 2014, 89, 1452-1459.	1.4	227
60	Association of Midlife to Late-Life Blood Pressure Patterns With Incident Dementia. JAMA - Journal of the American Medical Association, 2019, 322, 535.	3.8	227
61	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 2316.	3.8	223
62	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain, 2015, 138, 761-771.	3.7	222
63	Diagnostic Criteria for the Behavioral Variant of Frontotemporal Dementia (bvFTD): Current Limitations and Future Directions. Alzheimer Disease and Associated Disorders, 2007, 21, S14-S18.	0.6	219
64	Widespread brain tau and its association with ageing, Braak stage and Alzheimerâ€™s dementia. Brain, 2018, 141, 271-287.	3.7	218
65	Mild cognitive impairment due to Alzheimer disease in the community. Annals of Neurology, 2013, 74, 199-208.	2.8	215
66	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	7.1	213
67	Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders, 1997, 11 Suppl 2, S13-21.	0.6	213
68	Blood Pressure and White-Matter Disease Progression in a Biethnic Cohort. Stroke, 2010, 41, 3-8.	1.0	209
69	Mild cognitive impairment and dementia prevalence: The Atherosclerosis Risk in Communities Neurocognitive Study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 1-11.	1.2	209
70	Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2013, 12, 149-156.	4.9	204
71	Fourteenâ€year longitudinal study of vascular risk factors, APOE genotype, and cognition: The ARIC MRI Study. Alzheimer's and Dementia, 2009, 5, 207-214.	0.4	199
72	Mild cognitive impairment associated with limbic and neocortical lewy body disease: a clinicopathological study. Brain, 2010, 133, 540-556.	3.7	195

#	Article	IF	Citations
73	Vascular Dementia in a Population-Based Autopsy Study. Archives of Neurology, 2003, 60, 569.	4.9	194
74	TDP-43 represses cryptic exon inclusion in the FTDâ€“ALS gene UNC13A. Nature, 2022, 603, 124-130.	13.7	193
75	Essentials of the Proper Diagnoses of Mild Cognitive Impairment, Dementia, and Major Subtypes of Dementia. Mayo Clinic Proceedings, 2003, 78, 1290-1308.	1.4	187
76	Comparison of ¹⁸F-FDG and PiB PET in Cognitive Impairment. Journal of Nuclear Medicine, 2009, 50, 878-886.	2.8	183
77	Estimating the Number of Persons with Frontotemporal Lobar Degeneration in the US Population. Journal of Molecular Neuroscience, 2011, 45, 330-335.	1.1	183
78	Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology, 2013, 81, 1732-1740.	1.5	182
79	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Agingâ€“Alzheimerâ€™s Association Research Framework. JAMA Neurology, 2019, 76, 1174.	4.5	182
80	Antemortem diagnosis of frontotemporal lobar degeneration. Annals of Neurology, 2005, 57, 480-488.	2.8	181
81	Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology, 2014, 82, 1132-1141.	1.5	180
82	Subjective cognitive decline and risk of MCI. Neurology, 2018, 91, e300-e312.	1.5	176
83	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	4.9	175
84	Cardiac Disease Associated With Increased Risk of Nonamnestic Cognitive Impairment. JAMA Neurology, 2013, 70, 374.	4.5	173
85	Association of Duration and Severity of Diabetes Mellitus With Mild Cognitive Impairment. Archives of Neurology, 2008, 65, 1066-73.	4.9	171
86	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain, 2015, 138, 3747-3759.	3.7	170
87	Prominent phenotypic variability associated with mutations in Progranulin. Neurobiology of Aging, 2009, 30, 739-751.	1.5	166
88	Longitudinal Study of Death and Institutionalization in Patients with Primary Degenerative Dementia. Journal of the American Geriatrics Society, 1988, 36, 108-112.	1.3	165
89	Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiology of Aging, 2012, 33, 2091-2105.	1.5	162
90	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex, 2017, 97, 143-159.	1.1	162

#	Article	IF	Citations
91	Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Annals of Neurology, 2010, 67, 308-316.	2.8	160
92	Association of Lifetime Intellectual Enrichment With Cognitive Decline in the Older Population. JAMA Neurology, 2014, 71, 1017.	4.5	160
93	Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. JAMA Neurology, 2016, 73, 85.	4.5	160
94	Plasma and CSF neurofilament light. Neurology, 2019, 93, e252-e260.	1.5	160
95	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. Lancet Neurology, The, 2017, 16, 917-924.	4.9	159
96	Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment. Archives of Neurology, 2003, 60, 1777.	4.9	158
97	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. Neurobiology of Aging, 2017, 56, 172-179.	1.5	158
98	Brain injury biomarkers are not dependent on Î²â€amyloid in normal elderly. Annals of Neurology, 2013, 73, 472-480.	2.8	155
99	Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. NeuroImage, 2008, 42, 559-567.	2.1	152
100	AVâ€1451 tau and Î²â€amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of Neurology, 2017, 81, 58-67.	2.8	152
101	Association of Excessive Daytime Sleepiness With Longitudinal Î²-Amyloid Accumulation in Elderly Persons Without Dementia. JAMA Neurology, 2018, 75, 672.	4.5	150
102	Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging. JAMA Neurology, 2017, 74, 1073.	4.5	149
103	Utility of the Functional Activities Questionnaire for Distinguishing Mild Cognitive Impairment From Very Mild Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2010, 24, 348-353.	0.6	148
104	Alzheimer Disease: Postmortem Neuropathologic Correlates of Antemortem¹H MR Spectroscopy Metabolite Measurements¹. Radiology, 2008, 248, 210-220.	3.6	147
105	Rates of cerebral atrophy differ in different degenerative pathologies. Brain, 2006, 130, 1148-1158.	3.7	146
106	Dementia with Lewy bodies. Neurology, 2014, 83, 801-809.	1.5	143
107	Association of diabetes with amnestic and nonamnestic mild cognitiveÂimpairment. Alzheimer's and Dementia, 2014, 10, 18-26.	0.4	141
108	Patterns of Care in the Early Stages of Alzheimer's Disease: Impediments to Timely Diagnosis. Journal of the American Geriatrics Society, 2000, 48, 300-304.	1.3	139

#	Article	IF	Citations
109	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathologica, 2015, 129, 757-762.	3.9	139
110	A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology, 2017, 88, 1768-1775.	1.5	136
111	Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Annals of Neurology, 2017, 82, 706-718.	2.8	136
112	Multimorbidity and Risk of Mild Cognitive Impairment. Journal of the American Geriatrics Society, 2015, 63, 1783-1790.	1.3	135
113	Diabetes and Elevated Hemoglobin A1c Levels Are Associated with Brain Hypometabolism but Not Amyloid Accumulation. Journal of Nuclear Medicine, 2014, 55, 759-764.	2.8	134
114	Relative Intake of Macronutrients Impacts Risk of Mild Cognitive Impairment or Dementia. Journal of Alzheimer's Disease, 2012, 32, 329-339.	1.2	133
115	The bivariate distribution of amyloid-Î² and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	3.7	129
116	Retinal microvascular abnormalities and subclinical magnetic resonance imaging brain infarct: a prospective study. Brain, 2010, 133, 1987-1993.	3.7	127
117	White matter hyperintensities: relationship to amyloid and tau burden. Brain, 2019, 142, 2483-2491.	3.7	126
118	Vascular Imaging Abnormalities and Cognition. Stroke, 2015, 46, 433-440.	1.0	125
119	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathologica, 2017, 133, 705-715.	3.9	125
120	Practice Effects and Longitudinal Cognitive Change in Normal Aging vs. Incident Mild Cognitive Impairment and Dementia in The Mayo Clinic Study of Aging. Clinical Neuropsychologist, 2013, 27, 1247-1264.	1.5	124
121	Computed tomographic scan correlates of auditory comprehension deficits in aphasia: A prospective recovery study. Annals of Neurology, 1983, 13, 558-566.	2.8	123
122	Sleep characteristics and risk of dementia and Alzheimer's disease: The Atherosclerosis Risk in Communities Study. Alzheimer's and Dementia, 2018, 14, 157-166.	0.4	122
123	APOE Îµ4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology, 2018, 91, e1182-e1195.	1.5	122
124	Rates of Î²-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology, 2014, 82, 1605-1612.	1.5	119
125	The ARIC-PET amyloid imaging study. Neurology, 2016, 87, 473-480.	1.5	119
126	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. Journal of Neuroscience, 2014, 34, 16247-16255.	1.7	117

#	Article	IF	Citations
127	Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. Journal of Clinical Investigation, 2020, 130, 6080-6092.	3.9	117
128	Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science, 2016, 353, 708-712.	6.0	116
129	Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. JAMA Neurology, 2018, 75, 970.	4.5	116
130	Systemic inflammation during midlife and cognitive change over 20 years: The ARIC Study. Neurology, 2019, 92, e1256-e1267.	1.5	116
131	Arterial stiffness and dementia pathology. Neurology, 2018, 90, e1248-e1256.	1.5	114
132	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurology, 2021, 78, 1108.	4.5	114
133	Performance of plasma phosphorylated tau 181 and 217 in the community. Nature Medicine, 2022, 28, 1398-1405.	15.2	114
134	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiology of Aging, 2015, 36, 452-461.	1.5	113
135	Tauâ€positron emission tomography correlates with neuropathology findings. Alzheimer's and Dementia, 2020, 16, 561-571.	0.4	113
136	Association of Câ€reactive protein with mild cognitive impairment. Alzheimer's and Dementia, 2009, 5, 398-405.	0.4	111
137	Coronary heart disease is associated with non-amnestic mild cognitive impairment. Neurobiology of Aging, 2010, 31, 1894-1902.	1.5	111
138	Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. Alzheimer's and Dementia, 2017, 13, 168-177.	0.4	110
139	Alzheimer's Diseaseâ€"Related Dementias Summit 2016: National research priorities. Neurology, 2017, 89, 2381-2391.	1.5	109
140	18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiology of Aging, 2014, 35, 2096-2106.	1.5	108
141	Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort. Neurology, 2005, 65, 876-881.	1.5	107
142	Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a populationâ€based elderly cohort. Alzheimer's and Dementia, 2016, 12, 1226-1234.	0.4	107
143	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. JAMA Neurology, 2017, 74, 718.	4.5	107
144	Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome. Movement Disorders, 2009, 24, 1375-1379.	2.2	105

#	Article	IF	Citations
145	Vascular Risk Factors: Imaging and Neuropathologic Correlates. Journal of Alzheimer's Disease, 2010, 20, 699-709.	1.2	104
146	Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathologica, 2015, 130, 863-876.	3.9	104
147	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurology, The, 2016, 15, 56-64.	4.9	104
148	The Association of Late-Life Diabetes Status and Hyperglycemia With Incident Mild Cognitive Impairment and Dementia: The ARIC Study. Diabetes Care, 2019, 42, 1248-1254.	4.3	104
149	Revisiting FDA Approval of Aducanumab. New England Journal of Medicine, 2021, 385, 769-771.	13.9	104
150	Recommendations of the Alzheimer's Diseaseâ€“Related Dementias Conference. Neurology, 2014, 83, 851-860.	1.5	103
151	Impact of Differential Attrition on the Association of Education With Cognitive Change Over 20 Years of Follow-up: The ARIC Neurocognitive Study. American Journal of Epidemiology, 2014, 179, 956-966.	1.6	102
152	Neuropsychiatric symptoms, APOE Îµ4, and the risk of incident dementia. Neurology, 2015, 84, 935-943.	1.5	101
153	Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging. Neurology, 2015, 84, 1433-1442.	1.5	101
154	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. Alzheimer's and Dementia, 2018, 14, 563-575.	0.4	98
155	Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 1144-1153.	2.2	98
156	Midlife systemic inflammatory markers are associated with late-life brain volume. Neurology, 2017, 89, 2262-2270.	1.5	97
157	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97
158	MRI and MRS predictors of mild cognitive impairment in a population-based sample. Neurology, 2013, 81, 126-133.	1.5	95
159	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 83-91.	1.8	94
160	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.4	93
161	Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology, 2012, 79, 553-560.	1.5	91
162	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	3.9	90

#	Article	IF	Citations
163	Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathologica, 2015, 130, 559-573.	3.9	89
164	Decline in Weight and Incident Mild Cognitive Impairment. JAMA Neurology, 2016, 73, 439.	4.5	89
165	Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimer's and Dementia, 2022, 18, 1128-1140.	0.4	88
166	Measuring cognition and function in the preclinical stage of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 64-75.	1.8	87
167	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	3.9	87
168	Tauâ€PET uptake: Regional variation in average SUVR and impact of amyloid deposition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 21-30.	1.2	86
169	Survival Study of Vascular Dementia in Rochester, Minnesota. Archives of Neurology, 2003, 60, 85.	4.9	85
170	Performance of the CogState computerized battery in the Mayo ClinicÂStudy on Aging. Alzheimer's and Dementia, 2015, 11, 1367-1376.	0.4	85
171	Association of midlife lipids with 20â€year cognitive change: A cohort study. Alzheimer's and Dementia, 2018, 14, 167-177.	0.4	84
172	Midlife Systemic Inflammation, Late-Life White Matter Integrity, and Cerebral Small Vessel Disease. Stroke, 2017, 48, 3196-3202.	1.0	83
173	Association of Alzheimer's disease GWAS loci with MRI markers of brain aging. Neurobiology of Aging, 2015, 36, 1765.e7-1765.e16.	1.5	82
174	Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults. JAMA Neurology, 2017, 74, 801.	4.5	81
175	Diabetes, Prediabetes, and Brain Volumes and Subclinical Cerebrovascular Disease on MRI: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). Diabetes Care, 2017, 40, 1514-1521.	4.3	81
176	Progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a description of 55 cases and comparison to other phenotypes. Brain Communications, 2020, 2, fcaa068.	1.5	81
177	Utility of the global CDR^{Â®} plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. Alzheimer's and Dementia, 2020, 16, 106-117.	0.4	81
178	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1005-1014.	0.4	80
179	Comparison of Gait Parameters forÂPredicting Cognitive Decline: TheÂMayoÂClinic Study of Aging. Journal of Alzheimer's Disease, 2016, 55, 559-567.	1.2	79
180	Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. Sleep Medicine, 2017, 32, 236-243.	0.8	79

#	Article	IF	Citations
181	Metabolic Syndrome, Inflammation, and Nonamnestic Mild Cognitive Impairment in Older Persons. Alzheimer Disease and Associated Disorders, 2010, 24, 11-18.	0.6	78
182	Incidence and Causes of Nondegenerative Nonvascular Dementia. Archives of Neurology, 2006, 63, 218.	4.9	77
183	Impaired Lung Function, Lung Disease, and Risk of Incident Dementia. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1385-1396.	2.5	77
184	Anesthesia and Incident Dementia: A Population-Based, Nested, Case-Control Study. Mayo Clinic Proceedings, 2013, 88, 552-561.	1.4	76
185	In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathologica, 2017, 134, 255-269.	3.9	76
186	Hippocampal Volumes, Proton Magnetic Resonance Spectroscopy Metabolites, and Cerebrovascular Disease in Mild Cognitive Impairment Subtypes. Archives of Neurology, 2008, 65, 1621-8.	4.9	75
187	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiology of Aging, 2014, 35, 2421.e13-2421.e17.	1.5	74
188	Midlife vascular risk factors and midlife cognitive status in relation to prevalence of mild cognitive impairment and dementia in later life: The Atherosclerosis Risk in Communities Study. Alzheimer's and Dementia, 2018, 14, 1406-1415.	0.4	74
189	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	3.7	74
190	Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology, 2014, 82, 1959-1967.	1.5	73
191	[¹⁸F]AVâ€1451 tauâ€PET and primary progressive aphasia. Annals of Neurology, 2018, 83, 599-611.	2.8	73
192	Language and behavior domains enhance the value of the clinical dementia rating scale. Alzheimer's and Dementia, 2011, 7, 293-299.	0.4	72
193	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. Brain, 2019, 142, 1134-1147.	3.7	72
194	Effect of intellectual enrichment on AD biomarker trajectories. Neurology, 2016, 86, 1128-1135.	1.5	71
195	Association Between Mentally Stimulating Activities in Late Life and the Outcome of Incident Mild Cognitive Impairment, With an Analysis of the APOE Îµ4 Genotype. JAMA Neurology, 2017, 74, 332.	4.5	71
196	Argyrophilic grains: A distinct disease or an additive pathology?. Neurobiology of Aging, 2008, 29, 566-573.	1.5	70
197	Progranulin protein levels are differently regulated in plasma and CSF. Neurology, 2014, 82, 1871-1878.	1.5	70
198	Smoking and white matter hyperintensity progression. Neurology, 2015, 84, 841-848.	1.5	70

#	Article	IF	Citations
199	Long-term Retention of Implicitly Acquired Learning in Patients with Alzheimer's Disease. Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology, 1991, 13, 880-894.	1.4	69
200	Retinal Microvascular Signs and 10-Year Risk of Cerebral Atrophy. Stroke, 2010, 41, 1826-1828.	1.0	69
201	TYROBP genetic variants in early-onset Alzheimer's disease. Neurobiology of Aging, 2016, 48, 222.e9-222.e15.	1.5	69
202	Unaware learning versus preserved learning in pharmacologic amnesia: similarities and differences. Journal of Experimental Psychology: Learning Memory and Cognition, 1991, 17, 1017-29.	0.7	69
203	Association of Prior Stroke With Cognitive Function and Cognitive Impairment. Archives of Neurology, 2009, 66, 614-9.	4.9	68
204	Amyloid-Î² deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain, 2016, 139, 2740-2750.	3.7	68
205	Entorhinal cortex tau, amyloid-Î², cortical thickness and memory performance in non-demented subjects. Brain, 2019, 142, 1148-1160.	3.7	68
206	Artificial Intelligenceâ€“Electrocardiography to Predict Incident Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e009355.	2.1	68
207	Dementia and Cerebrovascular Disease. Mayo Clinic Proceedings, 2006, 81, 223-230.	1.4	67
208	Associations of microalbuminuria with brain atrophy and white matter hyperintensities in hypertensive sibships. Journal of the Neurological Sciences, 2008, 271, 53-60.	0.3	67
209	Spectrum of cognition short of dementia. Neurology, 2015, 85, 1712-1721.	1.5	67
210	Obesity, Insulin Resistance, and Incident Small Vessel Disease on Magnetic Resonance Imaging. Stroke, 2015, 46, 3131-3136.	1.0	67
211	Genome-wide Studies of Verbal Declarative Memory in Nondemented Older People: The Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium. Biological Psychiatry, 2015, 77, 749-763.	0.7	67
212	[¹⁸F]AVâ€‘1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology, 2018, 83, 248-257.	2.8	67
213	FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain, 2018, 141, 1201-1217.	3.7	67
214	Frequency of LATE neuropathologic change across the spectrum of Alzheimerâ€™s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. Acta Neuropathologica, 2022, 144, 27-44.	3.9	67
215	Incidence of Vascular Dementia in Rochester, Minn, 1985-1989. Archives of Neurology, 2002, 59, 1605.	4.9	66
216	Developmental Aspects of the Intracerebral Microvasculature and Perivascular Spaces: Insights into Brain Response to Late-Life Diseases. Journal of Neuropathology and Experimental Neurology, 2011, 70, 1060-1069.	0.9	66

#	Article	IF	Citations
217	Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. JAMA Neurology, 2019, 76, 187.	4.5	66
218	Withdrawal of Neuroleptic Medications from Institutionalized Dementia Patients: Results of a Double-Blind, Baseline-Treatmentâ€"Controlled Pilot Study. Journal of Geriatric Psychiatry and Neurology, 1997, 10, 119-126.	1.2	65
219	Selective Worsening of Brain Injury Biomarker Abnormalities in Cognitively Normal Elderly Persons With Î²-Amyloidosis. JAMA Neurology, 2013, 70, 1030.	4.5	65
220	Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2016, 53, 573-581.	1.2	65
221	Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials. Brain, 2019, 142, 443-459.	3.7	65
222	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathologica, 2019, 137, 227-238.	3.9	65
223	Î²-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.5	65
224	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. , 2014, 10, S430-S452.		64
225	Intracranial atherosclerosis and dementia. Neurology, 2017, 88, 1556-1563.	1.5	64
226	Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Molecular Neurodegeneration, 2014, 9, 38.	4.4	63
227	Neuroimaging Correlates of Cerebral Microbleeds. Stroke, 2017, 48, 2964-2972.	1.0	63
228	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433.	2.1	63
229	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.5	62
230	Î²-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.5	62
231	Characteristics of the dementia in lateâ€onset metachromatic leukodystrophy. Neurology, 1994, 44, 662-662.	1.5	62
232	Risk and protective factors for cognitive impairment in persons aged 85 years and older. Neurology, 2015, 84, 1854-1861.	1.5	61
233	Comparison of Imaging Biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging. Archives of Neurology, 2012, 69, 614.	4.9	60
234	In vivo ¹⁸ F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology, 2018, 90, e947-e954.	1.5	60

#	Article	IF	Citations
235	Midlife cardiovascular health and 20â€year cognitive decline: Atherosclerosis Risk in Communities Study results. Alzheimer's and Dementia, 2018, 14, 579-589.	0.4	60
236	Association of Apolipoprotein E Îµ4 With Transactive Response DNA-Binding Protein 43. JAMA Neurology, 2018, 75, 1347.	4.5	60
237	Cognitive outcomes of patients undergoing therapeutic hypothermia after cardiac arrest. Neurology, 2013, 81, 40-45.	1.5	59
238	Lifeâ€course blood pressure in relation to brain volumes. Alzheimer's and Dementia, 2016, 12, 890-899.	0.4	59
239	The association of mid-to late-life systemic inflammation with white matter structure in older adults: The Atherosclerosis Risk in Communities Study. Neurobiology of Aging, 2018, 68, 26-33.	1.5	59
240	Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimer's and Dementia, 2016, 12, 391-398.	0.4	58
241	The critical role Wernicke's area in sentence repetition. Annals of Neurology, 1985, 17, 549-557.	2.8	57
242	Off-Label Medication Use in Frontotemporal Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2010, 25, 128-133.	0.9	57
243	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. JAMA Neurology, 2014, 71, 1547.	4.5	57
244	Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARICâ€NCS). Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 73-82.	1.2	57
245	Alzheimer Disease. Mayo Clinic Proceedings, 2017, 92, 978-994.	1.4	57
246	Lowering of Amyloid-Beta by Î²-Secretase Inhibitors â€" Some Informative Failures. New England Journal of Medicine, 2019, 380, 1476-1478.	13.9	56
247	The neuropsychology of normal aging and preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 84-92.	0.4	55
248	Normative Data for 8 Neuropsychological Tests in Older Blacks and Whites From the Atherosclerosis Risk in Communities (ARIC) Study. Alzheimer Disease and Associated Disorders, 2015, 29, 32-44.	0.6	55
249	Association of Mild Cognitive Impairment WithÂExposure to General Anesthesia for Surgical and Nonsurgical Procedures. Mayo Clinic Proceedings, 2016, 91, 208-217.	1.4	55
250	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. Neurology, 2018, 90, e466-e473.	1.5	55
251	Midlife and Lateâ€Life Vascular Risk Factors and White Matter Microstructural Integrity: The Atherosclerosis Risk in Communities Neurocognitive Study. Journal of the American Heart Association, 2017, 6, .	1.6	54
252	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. NeuroImage: Clinical, 2019, 23, 101823.	1.4	54

#	Article	IF	Citations
253	Cortical Î²-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging. Translational Psychiatry, 2019, 9, 123.	2.4	54
254	Association of Central Arterial Stiffness and Pressure Pulsatility with Mild Cognitive Impairment and Dementia: The Atherosclerosis Risk in Communities Study-Neurocognitive Study (ARIC-NCS). Journal of Alzheimer's Disease, 2017, 57, 195-204.	1.2	53
255	Cerebral microbleeds. Neurology, 2019, 92, e253-e262.	1.5	53
256	Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. International Psychogeriatrics, 2018, 30, 245-251.	0.6	52
257	A brief history of â€œAlzheimer diseaseâ€• Neurology, 2019, 92, 1053-1059.	1.5	52
258	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.5	52
259	Deep learning-based brain age prediction in normal aging and dementia. Nature Aging, 2022, 2, 412-424.	5.3	52
260	Heart Disease and Dementia: A Population-based Study. American Journal of Epidemiology, 2006, 163, 135-141.	1.6	51
261	Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals. Annals of Neurology, 2017, 81, 871-882.	2.8	51
262	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. Neurobiology of Aging, 2019, 77, 26-36.	1.5	51
263	Longitudinal neuroimaging biomarkers differ across Alzheimerâ€™s disease phenotypes. Brain, 2020, 143, 2281-2294.	3.7	51
264	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 2018, 84, 705-716.	2.8	49
265	Computerized Analysis of Speech and Language to Identify Psycholinguistic Correlates of Frontotemporal Lobar Degeneration. Cognitive and Behavioral Neurology, 2010, 23, 165-177.	0.5	48
266	The advantages of frontotemporal degeneration drug development (partÂ2Âof frontotemporal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22	0.4	48
267	Hypothyroidism and Risk of Mild Cognitive Impairment in Elderly Persons. JAMA Neurology, 2014, 71, 201.	4.5	48
268	Duration and Pathologic Correlates of Lewy Body Disease. JAMA Neurology, 2017, 74, 310.	4.5	48
269	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. Alzheimer's and Dementia, 2019, 15, 927-939.	0.4	48
270	A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. Journal of Alzheimer's Disease, 2019, 67, 181-195.	1.2	48

#	Article	IF	Citations
271	Use of the CDRÂ® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium. Alzheimer's and Dementia, 2020, 16, 79-90.	0.4	48
272	MRI Correlates of Protein Deposition and Disease Severity in Postmortem Frontotemporal Lobar Degeneration. Neurodegenerative Diseases, 2009, 6, 106-117.	0.8	47
273	Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status. Clinical Neuropsychologist, 2017, 31, 99-117.	1.5	47
274	Subtypes of dementia with Lewy bodies are associated with Î±-synuclein and tau distribution. Neurology, 2020, 95, e155-e165.	1.5	47
275	Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. Neurology, 2013, 80, 2130-2137.	1.5	46
276	Correlates of Dementia and Mild Cognitive Impairment in Patients With Atrial Fibrillation: The Atherosclerosis Risk in Communities Neurocognitive Study (ARICâ€NCS). Journal of the American Heart Association, 2017, 6, .	1.6	46
277	Association of Ischemic Stroke Incidence, Severity, and Recurrence With Dementia in the Atherosclerosis Risk in Communities Cohort Study. JAMA Neurology, 2022, 79, 271.	4.5	46
278	Invited Commentary: Albuminuria and Microvascular Disease of the Brain--A Shared Pathophysiology. American Journal of Epidemiology, 2010, 171, 287-289.	1.6	45
279	Predicting functional decline in behavioural variant frontotemporal dementia. Brain, 2011, 134, 432-448.	3.7	45
280	Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimerâ€™s disease using the Multiple Sleep Latency Test. Alzheimer's Research and Therapy, 2014, 6, 76.	3.0	45
281	Antemortem MRI findings associated with microinfarcts at autopsy. Neurology, 2014, 82, 1951-1958.	1.5	45
282	Influence of amyloid and APOE on cognitive performance in a late middleâ€aged cohort. Alzheimer's and Dementia, 2016, 12, 281-291.	0.4	45
283	Association of Brain Magnetic Resonance Imaging Signs With Cognitive Outcomes in Persons With Nonimpaired Cognition and Mild Cognitive Impairment. JAMA Network Open, 2019, 2, e193359.	2.8	45
284	Dementia in late-onset epilepsy. Neurology, 2020, 95, e3248-e3256.	1.5	45
285	Protein contributions to brain atrophy acceleration in Alzheimerâ€™s disease and primary age-related tauopathy. Brain, 2020, 143, 3463-3476.	3.7	45
286	Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?. NeuroImage: Clinical, 2013, 2, 249-257.	1.4	44
287	Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment. Neurology, 2016, 87, 2317-2323.	1.5	44
288	Leisureâ€time physical activity sustained since midlife and preservation of cognitive function: The Atherosclerosis Risk in Communities Study. Alzheimer's and Dementia, 2019, 15, 273-281.	0.4	44

#	Article	IF	Citations
289	Patterns of Brain Atrophy in Clinical Variants of Frontotemporal Lobar Degeneration. Dementia and Geriatric Cognitive Disorders, 2013, 35, 34-50.	0.7	42
290	The Brain in Kidney Disease (BRINK) Cohort Study: Design and Baseline Cognitive Function. American Journal of Kidney Diseases, 2016, 67, 593-600.	2.1	42
291	The Cross-sectional and Longitudinal Associations Between IL-6, IL-10, and TNFÎ± and Cognitive Outcomes in the Mayo Clinic Study of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1289-1295.	1.7	42
292	Mortality in Mild Cognitive Impairment Varies by Subtype, Sex, and Lifestyle Factors: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2015, 45, 1237-1245.	1.2	41
293	The role of cerebrovascular disease when there is concomitant Alzheimer disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 952-956.	1.8	41
294	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 257-266.	0.4	41
295	Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging. Journal of the American Geriatrics Society, 2017, 65, 792-799.	1.3	41
296	Association of Apolipoprotein E É›4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. JAMA Network Open, 2019, 2, e1913909.	2.8	41
297	Neuropsychological subtypes of incident mild cognitive impairment in the Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2019, 15, 878-887.	0.4	41
298	Social support and cognition in a community-based cohort: the Atherosclerosis Risk in Communities (ARIC) study. Age and Ageing, 2016, 45, 475-480.	0.7	40
299	Prevalence and Natural History of Superficial Siderosis. Stroke, 2017, 48, 3210-3214.	1.0	40
300	Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Annals of Clinical and Translational Neurology, 2018, 5, 1250-1263.	1.7	40
301	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. Acta Neuropathologica Communications, 2019, 7, 150.	2.4	40
302	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. Annals of Neurology, 2019, 86, 866-877.	2.8	40
303	Passive caseâ€finding for Alzheimer's disease and dementia in two U.S. communities. Alzheimer's and Dementia, 2011, 7, 53-60.	0.4	39
304	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. Stroke, 2019, 50, 3037-3044.	1.0	39
305	Longitudinal structural and metabolic changes in frontotemporal dementia. Neurology, 2020, 95, e140-e154.	1.5	39
306	Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease. NeuroImage, 2015, 113, 61-69.	2.1	38

#	Article	IF	Citations
307	Comparison of variables associated with cerebrospinal fluid neurofilament, totalâ€tau, and neurogranin. Alzheimer's and Dementia, 2019, 15, 1437-1447.	0.4	38
308	Quantity and quality of mental activities and the risk of incident mild cognitive impairment. Neurology, 2019, 93, e548-e558.	1.5	38
309	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 37-48.	0.4	38
310	Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition. Brain Communications, 2021, 3, fcab106.	1.5	38
311	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. NeuroImage, 2021, 231, 117845.	2.1	38
312	White Matter Reference Region in PET Studies of ¹¹C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-Î² Deposition. Journal of Nuclear Medicine, 2018, 59, 1583-1589.	2.8	37
313	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	3.7	37
314	APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Science Translational Medicine, 2021, 13, eabc9375.	5.8	37
315	Type 2 Diabetes and Cognitive Decline Over 14 Years in Middle-Aged African Americans and Whites: The ARIC Brain MRI Study. Neuroepidemiology, 2014, 43, 220-227.	1.1	36
316	Disrupted functional connectivity in primary progressive apraxia of speech. NeuroImage: Clinical, 2018, 18, 617-629.	1.4	36
317	Clinical Features of Pathologic Subtypes of Behavioral-Variant Frontotemporal Dementia. Archives of Neurology, 2007, 64, 1611.	4.9	35
318	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiology of Aging, 2015, 36, 2010-2017.	1.5	35
319	FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2016, 53, 1609-1616.	1.2	35
320	Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation. Alzheimer's and Dementia, 2017, 13, 267-273.	0.4	35
321	Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum. Mayo Clinic Proceedings, 2019, 94, 1516-1523.	1.4	35
322	Bad news and good news in AD, and how to reconcile them. Nature Reviews Neurology, 2019, 15, 61-62.	4.9	35
323	Clinical Trial Design Issues in Mild to Moderate Alzheimer Disease. Cognitive and Behavioral Neurology, 2008, 21, 197-201.	0.5	34
324	Differences in rate of functional decline across three dementia types. Alzheimer's and Dementia, 2013, 9, S63-71.	0.4	34

#	Article	IF	Citations
325	Network-driven plasma proteomics expose molecular changes in the Alzheimerâ€™s brain. Molecular Neurodegeneration, 2016, 11, 31.	4.4	34
326	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 739-749.	1.4	34
327	Mediterranean Diet and Late-Life Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 686.	3.8	33
328	Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism and Related Disorders, 2016, 28, 41-48.	1.1	33
329	[P2â€“415]: THE MAYO CLINIC ADULT LIFESPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2017, 13, P792.	0.4	33
330	Leisure-Time Physical Activity and the Risk of Incident Dementia: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2018, 63, 149-155.	1.2	33
331	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. Brain, 2019, 142, 2466-2482.	3.7	33
332	MRI Outperforms [18F]AVâ€1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 105-113.	2.2	33
333	Mayo Normative Studies: Regression-Based Normative Data for the Auditory Verbal Learning Test for Ages 30â€“91 Years and the Importance of Adjusting for Sex. Journal of the International Neuropsychological Society, 2021, 27, 211-226.	1.2	33
334	Albuminuria and Estimated GFR as Risk Factors for Dementia in Midlife and Older Age: Findings From the ARIC Study. American Journal of Kidney Diseases, 2020, 76, 775-783.	2.1	33
335	Brain Aging in African-Americans: The Atherosclerosis Risk in Communities (ARIC) Experience. Current Alzheimer Research, 2015, 12, 607-613.	0.7	33
336	Dietary antioxidant intake and cognitive performance in middle-aged adults. Public Health Nutrition, 2000, 3, 337-343.	1.1	32
337	Current treatment of mild cognitive impairment and alzheimerâ€™s disease. Current Neurology and Neuroscience Reports, 2006, 6, 365-371.	2.0	32
338	Association of hospitalization with long-term cognitive and brain MRI changes in the ARIC cohort. Neurology, 2015, 84, 1443-1453.	1.5	32
339	MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimer's and Dementia, 2016, 12, 1297-1304.	0.4	32
340	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Movement Disorders, 2016, 31, 989-994.	2.2	32
341	Association of white matter microstructural integrity with cognition and dementia. Neurobiology of Aging, 2019, 83, 63-72.	1.5	32
342	Predicting Progression to Mild Cognitive Impairment. Annals of Neurology, 2019, 85, 155-160.	2.8	32

#	Article	IF	Citations
343	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.4	32
344	The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. Alzheimer's and Dementia, 2020, 16, 22-36.	0.4	32
345	A computational model of neurodegeneration in Alzheimerâ€™s disease. Nature Communications, 2022, 13, 1643.	5.8	32
346	Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimer's Research and Therapy, 2021, 13, 199.	3.0	32
347	Characterizing cognitive performance in a large longitudinal study of aging with computerized semantic indices of verbal fluency. Neuropsychologia, 2016, 89, 42-56.	0.7	31
348	Genome-wide association study of 23,500 individuals identifies 7 loci associated with brain ventricular volume. Nature Communications, 2018, 9, 3945.	5.8	31
349	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. NeuroImage: Clinical, 2018, 19, 939-947.	1.4	31
350	Retinal signs and risk of incident dementia in the Atherosclerosis Risk in Communities study. Alzheimer's and Dementia, 2019, 15, 477-486.	0.4	31
351	Cerebral microbleed incidence, relationship to amyloid burden. Neurology, 2020, 94, e190-e199.	1.5	31
352	<scp>NIAâ€AA</scp> Alzheimer's Disease Framework: Clinical Characterization of Stages. Annals of Neurology, 2021, 89, 1145-1156.	2.8	31
353	Age and apoE associations with complex pathologic features in Alzheimer's disease. Journal of the Neurological Sciences, 2008, 273, 34-39.	0.3	30
354	Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study. Journal of Alzheimer's Disease, 2016, 55, 1069-1082.	1.2	30
355	LRRK2 variation and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 98-103.	1.1	30
356	The association between peripheral total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging. Neurobiology of Aging, 2018, 66, 68-74.	1.5	30
357	Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1244-1250.	1.7	30
358	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. Mayo Clinic Proceedings, 2020, 95, 1195-1205.	1.4	30
359	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. Brain, 2022, 145, 1079-1097.	3.7	30
360	Comparison of [18 F]Flutemetamol and [11 C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. NeuroImage: Clinical, 2017, 16, 295-302.	1.4	30

#	Article	IF	Citations
361	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiology of Aging, 2014, 35, 1483-1490.	1.5	29
362	A robust biomarker of largeâ€scale network failure in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 152-161.	1.2	29
363	Decreased Glutamate Levels in Patients with Amnestic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiBâ€PET Study. Journal of Neuroimaging, 2017, 27, 630-636.	1.0	29
364	Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 1-10.	1.2	29
365	Retinal signs and 20-year cognitive decline in the Atherosclerosis Risk in Communities Study. Neurology, 2018, 90, e1158-e1166.	1.5	29
366	Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods. NeuroImage: Clinical, 2019, 21, 101605.	1.4	29
367	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. Neurology, 2020, 94, e1793-e1802.	1.5	28
368	Detection of Alzheimer's disease amyloid beta 1â€42, pâ€tau, and tâ€tau assays. Alzheimer's and Dementia, 2022, 18, 635-644.	0.4	28
369	Incidence of Dementia Among Participants and Nonparticipants in a Longitudinal Study of Cognitive Aging. American Journal of Epidemiology, 2014, 180, 414-423.	1.6	27
370	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. Parkinsonism and Related Disorders, 2015, 21, 1101-1104.	1.1	27
371	Multimorbidity and neuroimaging biomarkers among cognitively normal persons. Neurology, 2016, 86, 2077-2084.	1.5	27
372	Joint associations of Î²-amyloidosis and cortical thickness with cognition. Neurobiology of Aging, 2018, 65, 121-131.	1.5	27
373	Prevalence and Risk of Severe Cognitive Impairment in Advanced Chronic Kidney Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 393-399.	1.7	27
374	Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration. Alzheimer's and Dementia, 2020, 16, 91-105.	0.4	27
375	Association of Intracranial Atherosclerotic Disease With Brain Î²-Amyloid Deposition. JAMA Neurology, 2020, 77, 350.	4.5	27
376	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 49-59.	0.4	27
377	Reduced fractional anisotropy of the genu of the corpus callosum as a cerebrovascular disease marker and predictor of longitudinal cognition in MCI. Neurobiology of Aging, 2020, 96, 176-183.	1.5	27
378	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology, 2020, 95, e23-e34.	1.5	27

#	Article	IF	Citations
379	Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort. Alzheimer's and Dementia, 2020, 16, 60-70.	0.4	27
380	Association of Initial Î²-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. JAMA Neurology, 2021, 78, 217.	4.5	27
381	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage: Clinical, 2021, 31, 102754.	1.4	27
382	The Metabolic Syndrome and Cognitive Decline in the Atherosclerosis Risk in Communities Study (ARIC). Dementia and Geriatric Cognitive Disorders, 2014, 38, 337-346.	0.7	26
383	Contributions of imprecision in <scp>PET</scp>â€<scp>MRI</scp> rigid registration to imprecision in amyloid <scp>PET</scp><scp>SUVR</scp> measurements. Human Brain Mapping, 2017, 38, 3323-3336.	1.9	26
384	¹⁸Fâ€AVâ€1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. Movement Disorders, 2019, 34, 344-352.	2.2	26
385	A soluble truncated tau species related to cognitive dysfunction is elevated in the brain of cognitively impaired human individuals. Scientific Reports, 2020, 10, 3869.	1.6	26
386	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain, 2021, 144, 3212-3225.	3.7	26
387	Time-to-event voxel-based techniques to assess regional atrophy associated with MCI risk of progression to AD. NeuroImage, 2011, 54, 985-991.	2.1	25
388	Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the populationâ€based Mayo Clinic Study of Aging. International Journal of Geriatric Psychiatry, 2018, 33, 1114-1120.	1.3	25
389	Population-Based Evaluation of Lumbar Puncture Opening Pressures. Frontiers in Neurology, 2019, 10, 899.	1.1	25
390	Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimerâ€™s Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 76, 261-274.	1.2	25
391	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. Frontiers in Aging Neuroscience, 2019, 11, 355.	1.7	25
392	Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging. American Journal of Geriatric Psychiatry, 2021, 29, 179-191.	0.6	25
393	Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks. Neurology, 2021, 97, 545-547.	1.5	25
394	MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease. Journal of Neuroimaging, 2015, 25, 269-274.	1.0	24
395	Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. Neurology, 2018, 90, e940-e946.	1.5	24
396	Chronic Systemic Inflammation Is Associated With Symptoms of Late-Life Depression: The ARIC Study. American Journal of Geriatric Psychiatry, 2020, 28, 87-98.	0.6	24

#	Article	IF	Citations
397	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. NeuroImage, 2021, 238, 118259.	2.1	24
398	Progressive familial leukodystrophy of late onset. Neurology, 1996, 46, 429-434.	1.5	23
399	Diabetes is Associated with Worse ExecutiveÂFunction in Both Eastern andÂWestern Populations: Shanghai Aging Study andÂMayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2015, 47, 167-176.	1.2	23
400	Role of Î²-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. JAMA Neurology, 2015, 72, 1475.	4.5	23
401	Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. Alzheimer's and Dementia, 2016, 12, 510-515.	0.4	23
402	Timing of Physical Activity, Apolipoprotein E Îµ4 Genotype, and Risk of Incident Mild Cognitive Impairment. Journal of the American Geriatrics Society, 2016, 64, 2479-2486.	1.3	23
403	Statins and Brain Health: Alzheimerâ€™s Disease and Cerebrovascular Disease Biomarkers in Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1345-1352.	1.2	23
404	Brain imaging measurements of fibrillar amyloidâ€Î² burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE Îµ4 allele. Alzheimer's and Dementia, 2020, 16, 598-609.	0.4	23
405	Revised Self-Monitoring Scale. Neurology, 2020, 94, e2384-e2395.	1.5	23
406	First PET Imaging Studies With ⁶³Zn-Zinc Citrate in Healthy Human Participants and Patients With Alzheimer Disease. Molecular Imaging, 2016, 15, 153601211667379.	0.7	22
407	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. Neurology, 2016, 87, 691-698.	1.5	22
408	[ICâ€Pâ€122]: THE MAYO CLINIC ADULT LIFE SPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFE SPAN. Alzheimer's and Dementia, 2017, 13, P93.	0.4	22
409	Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers. Journal of Alzheimer's Disease, 2018, 64, 281-290.	1.2	22
410	Rates of lobar atrophy in asymptomatic MAPT mutation carriers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 338-346.	1.8	22
411	Association of Dietary Patterns in Midlife and Cognitive Function in Later Life in US Adults Without Dementia. JAMA Network Open, 2019, 2, e1916641.	2.8	22
412	Association of Longitudinal Î²-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. JAMA Network Open, 2019, 2, e1916439.	2.8	22
413	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. Neurobiology of Aging, 2016, 45, 107-108.	1.5	21
414	Olfactory function and neurocognitive outcomes in old age: The Atherosclerosis Risk in Communities Neurocognitive Study. Alzheimer's and Dementia, 2018, 14, 1015-1021.	0.4	21

#	Article	IF	Citations
415	Brain volumetric deficits in MAPT mutation carriers: a multisite study. Annals of Clinical and Translational Neurology, 2021, 8, 95-110.	1.7	21
416	Observations on the shortâ€term 'natural history' of probable Alzheimer's disease in a controlled clinical trial. Neurology, 1994, 44, 260-260.	1.5	21
417	Pharmacotheraphy for Alzheimerâ€™s disease. Current Neurology and Neuroscience Reports, 2001, 1, 428-434.	2.0	20
418	Appraisal of cognition in preclinical Alzheimerâ€™s disease: a conceptual review. Neurodegenerative Disease Management, 2012, 2, 183-195.	1.2	20
419	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiology of Aging, 2016, 46, 32-42.	1.5	20
420	The Association of Mid- and Late-Life Systemic Inflammation with Brain Amyloid Deposition: The ARIC-PET Study. Journal of Alzheimer's Disease, 2018, 66, 1041-1052.	1.2	20
421	TDP-43 and Alzheimerâ€™s Disease Pathologic Subtype in Non-Amnestic Alzheimerâ€™s Disease Dementia. Journal of Alzheimer's Disease, 2018, 64, 1227-1233.	1.2	20
422	Association Between Critical Care Admissions and Cognitive Trajectories in Older Adults*. Critical Care Medicine, 2019, 47, 1116-1124.	0.4	20
423	Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2020, 16, 1013-1022.	0.4	20
424	Plasma amyloid Î² levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genomeâ€wide association study in over 12,000 nonâ€demented participants. Alzheimer's and Dementia, 2021, 17, 1663-1674.	0.4	20
425	Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Alzheimer's and Dementia, 2022, 18, 602-611.	0.4	20
426	Genetic variants associated with risk of Alzheimer's disease contribute to cognitive change in midlife: The Atherosclerosis Risk in Communities Study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 269-282.	1.1	19
427	Recurrent perseverations on semantic verbal fluency tasks as an early marker of cognitive impairment. Journal of Clinical and Experimental Neuropsychology, 2018, 40, 832-840.	0.8	19
428	Elevated medial temporal lobe and pervasive brain tauâ€PET signal in normal participants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 210-216.	1.2	19
429	Recommendations for the nomenclature of cognitive change associated with anaesthesia and surgeryâ€”2018. Acta Anaesthesiologica Scandinavica, 2018, 62, 1473-1480.	0.7	19
430	Cerebrospinal fluid dynamics disorders. Neurology, 2019, 93, e2237-e2246.	1.5	19
431	Linear vs volume measures of ventricle size. Neurology, 2020, 94, e549-e556.	1.5	19
432	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants. JAMA Network Open, 2020, 3, e2022847.	2.8	19

#	Article	IF	Citations
433	The temporal onset of the core features in dementia with Lewy bodies. Alzheimer's and Dementia, 2022, 18, 591-601.	0.4	19
434	¹ H-MRS metabolites and rate of Î²-amyloid accumulation on serial PET in clinically normal adults. Neurology, 2017, 89, 1391-1399.	1.5	18
435	Serum Vitamin D Concentrations and Cognitive Change Over 20 Years: The Atherosclerosis Risk in Communities Neurocognitive Study. Neuroepidemiology, 2018, 51, 131-137.	1.1	18
436	Automatic extraction and assessment of lifestyle exposures for Alzheimerâ€™s disease using natural language processing. International Journal of Medical Informatics, 2019, 130, 103943.	1.6	18
437	An agnostic reevaluation of the amyloid cascade hypothesis of Alzheimer's disease pathogenesis: The role of APP homeostasis. Alzheimer's and Dementia, 2020, 16, 1582-1590.	0.4	18
438	Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults. Neurology, 2020, 94, e1571-e1579.	1.5	18
439	Association of Hospitalization with Longâ€Term Cognitive Trajectories in Older Adults. Journal of the American Geriatrics Society, 2021, 69, 660-668.	1.3	18
440	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimerâ€™s pathophysiology. Acta Neuropathologica Communications, 2021, 9, 48.	2.4	18
441	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. Alzheimer's and Dementia, 2021, 17, 801-812.	0.4	18
442	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiology of Aging, 2021, 105, 252-261.	1.5	18
443	Frontal lobe ¹ H MR spectroscopy in asymptomatic and symptomatic MAPT mutation carriers. Neurology, 2019, 93, e758-e765.	1.5	18
444	Detecting clinical change with the CDRâ€FTLD: differences between FTLD and AD dementia. International Journal of Geriatric Psychiatry, 2017, 32, 977-982.	1.3	17
445	18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. Brain Communications, 2020, 2, fcaa040.	1.5	17
446	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. Annals of Neurology, 2020, 87, 556-567.	2.8	17
447	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721.	1.7	17
448	Long-read targeted sequencing uncovers clinicopathological associations for C9orf72-linked diseases. Brain, 2021, 144, 1082-1088.	3.7	17
449	Pickâ€™s disease: clinicopathologic characterization of 21 cases. Journal of Neurology, 2020, 267, 2697-2704.	1.8	17
450	Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2023, 19, 4498-4506.	0.4	17

#	Article	IF	Citations
451	Pharmacotherapy for Alzheimer's Disease: 2002. Clinical Neuropharmacology, 2003, 26, 93-101.	0.2	16
452	A computerized technique to assess language use patterns in patients with frontotemporal dementia. Journal of Neurolinguistics, 2010, 23, 127-144.	0.5	16
453	Utility of the Spanish version of the FTLD-modified CDR in the diagnosis and staging in frontotemporal lobar degeneration. Journal of the Neurological Sciences, 2014, 344, 63-68.	0.3	16
454	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurology: Genetics, 2016, 2, e85.	0.9	16
455	Cortical Thickness and Anxiety Symptoms Among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. Journal of Neuropsychiatry and Clinical Neurosciences, 2017, 29, 60-66.	0.9	16
456	The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 877-883.	1.7	16
457	Neuroimaging findings in midlife and risk of late-life dementia over 20 years of follow-up. Neurology, 2019, 92, e917-e923.	1.5	16
458	Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: The Mayo Clinic Study of Aging. International Journal of Geriatric Psychiatry, 2021, 36, 1362-1369.	1.3	16
459	Diagnostic accuracy of the Cogstate Brief Battery for prevalent MCI and prodromal AD (MCI) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.4	16
460	Longitudinal Tracking of FTLD. Alzheimer Disease and Associated Disorders, 2007, 21, S58-S63.	0.6	15
461	Î²-Amyloidosis and neurodegeneration in Alzheimer disease. Neurology, 2014, 82, 1756-1757.	1.5	15
462	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. Neurology, 2017, 89, 2039-2048.	1.5	15
463	Cortical Thickness and Depressive Symptoms in Cognitively Normal Individuals: The Mayo Clinic Study ofÂAging. Journal of Alzheimer's Disease, 2017, 58, 1273-1281.	1.2	15
464	Association Between Microinfarcts and Blood Pressure Trajectories. JAMA Neurology, 2018, 75, 212.	4.5	15
465	Relationships between Î²-amyloid and tau in an elderly population: An accelerated failure time model. NeuroImage, 2021, 242, 118440.	2.1	15
466	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Communications, 2022, 4, fcac013.	1.5	15
467	Alzheimer disease biomarkers and insights into mild cognitive impairment. Neurology, 2013, 80, 978-980.	1.5	14
468	Association of Hospitalization, Critical Illness, and Infection with Brain Structure in Older Adults. Journal of the American Geriatrics Society, 2018, 66, 1919-1926.	1.3	14

#	Article	IF	Citations
469	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	1.5	14
470	Brain atrophy in primary ageâ€related tauopathy is linked to transactive response DNAâ€binding protein of 43 kDa. Alzheimer's and Dementia, 2019, 15, 799-806.	0.4	14
471	Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. British Journal of Anaesthesia, 2020, 124, 594-602.	1.5	14
472	CSF biomarkers in Olmsted County. Neurology, 2020, 95, e256-e267.	1.5	14
473	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. Neurobiology of Aging, 2020, 88, 42-50.	1.5	14
474	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimerâ€™s Disease Neuropathological Changes. Journal of Alzheimer's Disease, 2020, 73, 1511-1523.	1.2	14
475	Associations Between Atrial Cardiopathy and Cerebral Amyloid: The ARICâ€PET Study. Journal of the American Heart Association, 2020, 9, e018399.	1.6	14
476	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. Acta Neuropathologica Communications, 2022, 10, 16.	2.4	14
477	A longitudinal investigation of AÎ², anxiety, depression, and mild cognitive impairment. Alzheimer's and Dementia, 2022, 18, 1824-1831.	0.4	14
478	Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia. Acta Neuropathologica, 2022, 144, 159-160.	3.9	14
479	Dementia in MS complicated by coexistent Alzheimer disease. Neurology: Clinical Practice, 2014, 4, 226-230.	0.8	13
480	Informant-based hearing difficulties and the risk for mild cognitive impairment and dementia. Age and Ageing, 2019, 48, 888-894.	0.7	13
481	Exposure to surgery under general anaesthesia and brain magnetic resonance imaging changes in older adults. British Journal of Anaesthesia, 2019, 123, 808-817.	1.5	13
482	Cognitive function after surgery with regional or general anesthesia: A populationâ€based study. Alzheimer's and Dementia, 2019, 15, 1243-1252.	0.4	13
483	Comparison of PC and iPad administrations of the Cogstate Brief Battery in the Mayo Clinic Study of Aging: Assessing cross-modality equivalence of computerized neuropsychological tests. Clinical Neuropsychologist, 2019, 33, 1102-1126.	1.5	13
484	Association between transactive response DNA-binding protein ofÂ43 kDa type and cognitive resilience to Alzheimerâ€™s disease: aÂcase-control study. Neurobiology of Aging, 2020, 92, 92-97.	1.5	13
485	Î²-Amyloid PET and ¹²³ I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. Neurology, 2021, 96, .	1.5	13
486	White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline. Brain Communications, 2021, 3, fcab076.	1.5	13

#	Article	IF	Citations
487	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. Journal of Neuroimaging, 2021, 31, 1020-1027.	1.0	13
488	Association of Midlife Plasma Amyloid-Î² Levels With Cognitive Impairment in Late Life. Neurology, 2021, 97, e1123-e1131.	1.5	13
489	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. Neurology, 2020, 95, e3190-e3202.	1.5	13
490	Language networks associated with computerized semantic indices. NeuroImage, 2015, 104, 125-137.	2.1	12
491	Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers. Neurology: Genetics, 2017, 3, e161.	0.9	12
492	Neural correlates of domain-specific cognitive decline. Neurology, 2019, 92, e1051-e1063.	1.5	12
493	Variants inPPP2R2BandIGF2BP3are associated with higher tau deposition. Brain Communications, 2020, 2, fcaa159.	1.5	12
494	Physical Activity and Trajectory of Cognitive Change in Older Persons: Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2021, 79, 377-388.	1.2	12
495	Prospective Analysis of Leisure-Time Physical Activity in Midlife and Beyond and Brain Damage on MRI in Older Adults. Neurology, 2021, 96, e964-e974.	1.5	12
496	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. Brain Communications, 2021, 3, fcab182.	1.5	12
497	Relationship Between Domain-Specific Cognitive Function and Speech-in-Noise Performance in Older Adults: The Atherosclerosis Risk in Communities Hearing Pilot Study. American Journal of Audiology, 2019, 28, 1006-1014.	0.5	12
498	The association of motoric cognitive risk with incident dementia and neuroimaging characteristics: The Atherosclerosis Risk in Communities Study. Alzheimer's and Dementia, 2022, 18, 434-444.	0.4	12
499	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Communications, 2022, 4, fcac017.	1.5	12
500	Alzheimer's disease and related dementias and heart failure: A community study. Journal of the American Geriatrics Society, 2022, 70, 1664-1672.	1.3	12
501	Incident Heart Failure and Cognitive Decline: The Atherosclerosis Risk in Communities Study. Journal of Cardiac Failure, 2017, 23, 47-55.	0.7	11
502	Patients come from populations and populations contain patients. A two-stage scientific and ethics review: The next adaptation for single institutional review boards. , 2017, 13, 940-946.		11
503	Incidence of frontotemporal disorders in Olmsted County: A populationâ€based study. Alzheimer's and Dementia, 2020, 16, 482-490.	0.4	11
504	Quality of life and caregiver burden in familial frontotemporal lobar degeneration: Analyses of symptomatic and asymptomatic individuals within the LEFFTDS cohort. Alzheimer's and Dementia, 2020, 16, 1115-1124.	0.4	11

#	Article	IF	Citations
505	Plasma phospholipid very-long-chain SFAs in midlife and 20-year cognitive change in the Atherosclerosis Risk in Communities (ARIC): a cohort study. American Journal of Clinical Nutrition, 2020, 111, 1252-1258.	2.2	11
506	The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. Neurobiology of Aging, 2021, 99, 11-18.	1.5	11
507	Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population. Brain Communications, 2021, 3, fcaa238.	1.5	11
508	The Relationship of APOE Îµ4, Race, and Sex on the Age of Onset and Risk of Dementia. Frontiers in Neurology, 2021, 12, 735036.	1.1	11
509	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. Movement Disorders, 2022, 37, 1256-1264.	2.2	11
510	Neuropathologic scales of cerebrovascular disease associated with diffusion changes on MRI. Acta Neuropathologica, 2022, 144, 1117-1125.	3.9	11
511	Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia. Journal of the American Geriatrics Society, 2018, 66, 2274-2281.	1.3	10
512	The influence of Î²-amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. Neurology, 2019, 92, e710-e722.	1.5	10
513	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-Î² PET Signal. Neurology, 2021, 97, e1799-e1808.	1.5	10
514	Talking points for physicians, patients and caregivers considering AduhelmÂ® infusion and the accelerated pathway for its approval by the FDA. Molecular Neurodegeneration, 2021, 16, 74.	4.4	10
515	Associations of Vascular Risk and Amyloid Burden with Subsequent Dementia. Annals of Neurology, 2022, 92, 607-619.	2.8	10
516	Tacrine for Alzheimer??s Disease. Pharmacoeconomics, 1995, 7, 275-279.	1.7	9
517	Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. Journal of Neuro-Oncology, 2018, 136, 373-378.	1.4	9
518	Association of non-exercise physical activity in mid- and late-life with cognitive trajectories and the impact of APOE Îµ4 genotype status: the Mayo Clinic Study of Aging. European Journal of Ageing, 2019, 16, 491-502.	1.2	9
519	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers. Journal of Neuroimaging, 2019, 29, 624-629.	1.0	9
520	Cognitive Reserve in Midlife is not Associated with Amyloid-Î² Deposition in Late-Life. Journal of Alzheimer's Disease, 2019, 68, 517-521.	1.2	9
521	The Enigma of Decreasing Dementia Incidence. JAMA Network Open, 2020, 3, e2011199.	2.8	9
522	Association of Cortical and Subcortical Î²-Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 2021, 33, 64-71.	0.9	9

#	Article	IF	Citations
523	Cerebral Microbleeds. Stroke, 2021, 52, 2347-2355.	1.0	9
524	1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. Neurobiology of Aging, 2022, 112, 16-26.	1.5	9
525	Deep learning identifies brain structures that predict cognition and explain heterogeneity in cognitive aging. NeuroImage, 2022, 251, 119020.	2.1	9
526	Donepezil 23 mg. Neurology: Clinical Practice, 2012, 2, 352-355.	0.8	8
527	Diagnostic tests for Alzheimer disease. Neurology: Clinical Practice, 2012, 2, 151-153.	0.8	8
528	The Telephone Interview for Cognitive Status. Cognitive and Behavioral Neurology, 2018, 31, 158-158.	0.5	8
529	Associations Between Left Ventricular Structure, Function, and Cerebral Amyloid. Stroke, 2019, 50, 3622-3624.	1.0	8
530	Elevated Plasma Ceramides Are Associated With Higher White Matter Hyperintensity Volumeâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2431-2436.	1.1	8
531	Functional Activity and Neuropsychiatric Symptoms in Normal Aging and Mild Cognitive Impairment. Alzheimer Disease and Associated Disorders, 2019, 33, 68-71.	0.6	8
532	Association of Hypertension According to New American College of Cardiology/American Heart Association Blood Pressure Guidelines With Incident Dementia in the ARIC Study Cohort. Journal of the American Heart Association, 2020, 9, e017546.	1.6	8
533	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. Journal of Alzheimer's Disease, 2021, 81, 113-122.	1.2	8
534	Sex Difference in the Relation Between Marital Status and Dementia Risk in Two Population-Based Cohorts. Journal of Alzheimer's Disease, 2021, 83, 1269-1279.	1.2	8
535	Causal structure discovery identifies risk factors and early brain markers related to evolution of white matter hyperintensities. NeuroImage: Clinical, 2022, 35, 103077.	1.4	8
536	Longâ€term tacrine treatment effects. Neurology, 1998, 50, 567-568.	1.5	7
537	Preclinical Alzheimer disease â€" the new frontier. Nature Reviews Neurology, 2016, 12, 620-621.	4.9	7
538	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	1.2	7
539	Prognosis of Patients with Behavioral Variant Frontotemporal Dementia Who have Focal Versus		

#	Article	IF	Citations
541	Highâ€Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change. Journal of the American Geriatrics Society, 2019, 67, 2353-2361.	1.3	7
542	Plasma Metabolites Associated with Brain MRI Measures of Neurodegeneration in Older Adults in the Atherosclerosis Risk in Communitiesâ€“Neurocognitive Study (ARIC-NCS). International Journal of Molecular Sciences, 2019, 20, 1744.	1.8	7
543	Longitudinal association between phosphatidylcholines, neuroimaging measures of Alzheimer's disease pathophysiology, and cognition in the Mayo Clinic Study of Aging. Neurobiology of Aging, 2019, 79, 43-49.	1.5	7
544	Associations Between Plasma Ceramides and Cerebral Microbleeds or Lacunes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2785-2793.	1.1	7
545	Brain MRI after critical care admission: A longitudinal imaging study. Journal of Critical Care, 2021, 62, 117-123.	1.0	7
546	TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death. Journal of Alzheimer's Disease, 2021, 80, 683-693.	1.2	7
547	Brain White Matter Structure and Amyloid Deposition in Black and White Older Adults: The ARICâ€PET Study. Journal of the American Heart Association, 2021, 10, e022087.	1.6	7
548	A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimerâ€™s Disease Based on Cogstate One Card Learning Accuracy Performance. Journal of Alzheimer's Disease, 2021, 83, 861-877.	1.2	7
549	Cerebrospinal Fluid Dynamics and Discordant Amyloid Biomarkers. Neurobiology of Aging, 2021, 110, 27-36.	1.5	7
550	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a series of clinical cases. Journal of Neurology, 2022, 269, 4110-4128.	1.8	7
551	Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying. , 2006, 2, 147-149.		6
552	Commentary on â€œMeta-analysis of six-month memantine trials in Alzheimer's disease.â€•Memantine has negligible benefits in mild to moderate Alzheimer's disease. , 2007, 3, 21-22.		6
553	Effects of age and dementia on temporal cycles in spontaneous speech fluency. Journal of Neurolinguistics, 2011, 24, 619-635.	0.5	6
554	Association of Pancreatic Polypeptide with Mild Cognitive Impairment Varies by APOE Îµ4 Allele. Frontiers in Aging Neuroscience, 2015, 7, 172.	1.7	6
555	Phenoconversion from probable rapid eye movement sleep behavior disorder to mild cognitive impairment to dementia in a populationâ€based sample. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 127-130.	1.2	6
556	Cerebrovascular disease affects brain structural integrity long before clinically overt strokes. Neurology, 2017, 89, 110-111.	1.5	6
557	Sifting through a failed Alzheimer trial. Neurology, 2018, 90, 447-448.	1.5	6
558	Endurance and gait speed relationships with mild cognitive impairment and dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12281.	1.2	6

#	Article	IF	Citations
559	Poly (ADP-Ribose) and Î±â€“synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity. PLoS ONE, 2022, 17, e0264446.	1.1	6
560	Association of Carotid Intima-Media Thickness with Brain MRI Markers in the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106388.	0.7	6
561	Artificial Intelligenceâ€“Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts. Mayo Clinic Proceedings, 2022, 97, 871-880.	1.4	6
562	Dementia: Many roads, but not built in a day. Neurology, 2007, 69, 2193-2194.	1.5	5
563	Frequency of Acute and Subacute Infarcts in a Population-Based Study. Mayo Clinic Proceedings, 2018, 93, 300-306.	1.4	5
564	Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech. Cortex, 2020, 124, 33-43.	1.1	5
565	Association of mid-life serum lipid levels with late-life brain volumes: The atherosclerosis risk in communities neurocognitive study (ARIC NCS). NeuroImage, 2020, 223, 117324.	2.1	5
566	Lack of physical activity, neuropsychiatric symptoms and the risk of incident mild cognitive impairment in older community-dwelling individuals. German Journal of Exercise and Sport Research, 2021, 51, 487-494.	1.0	5
567	Alzheimer Disease Spectrum. Neurology, 2021, 96, 299-300.	1.5	5
568	Amyloid- and tau-PET imaging in a familial prion kindred. Neurology: Genetics, 2018, 4, e290.	0.9	4
569	Non-right handed primary progressive apraxia of speech. Journal of the Neurological Sciences, 2018, 390, 246-254.	0.3	4
570	Mid- and Late-Life Leisure-Time Physical Activity and Global Brain Amyloid Burden: The Atherosclerosis Risk in Communities (ARIC)-PET Study. Journal of Alzheimer's Disease, 2020, 76, 139-147.	1.2	4
571	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. Journal of Neurology, 2020, 267, 1444-1453.	1.8	4
572	Distinguishing Frontotemporal Dementia From Alzheimer Disease Through Everyday Function Profiles: Trajectories of Change. Journal of Geriatric Psychiatry and Neurology, 2021, 34, 66-75.	1.2	4
573	Relation of Diabetes Mellitus to Incident Dementia in Patients With Atrial Fibrillation (from the) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.7	4
574	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. Journal of Alzheimer's Disease, 2022, 87, 1537-1547.	1.2	4
575	Kidney-Metabolic Factors Associated with Cognitive Impairment in Chronic Kidney Disease: A Pilot Study. American Journal of Nephrology, 2022, 53, 435-445.	1.4	4
576	Physical Frailty and Brain White Matter Abnormalities: The ARIC Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 0, , .	1.7	4

#	Article	IF	Citations
577	Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldtâ€“Jakob disease and autoimmune encephalitis. European Journal of Neurology, 2022, 29, 2905-2912.	1.7	4
578	Healthy young hearts sharper older minds make. Annals of Neurology, 2013, 73, 151-152.	2.8	3
579	ICâ€Pâ€127: VARIABILITY IN MRI AND PET MEASUREMENTS INTRODUCED BY CHANGE IN MRI VENDOR. Alzheimer's and Dementia, 2019, 15, P104.	0.4	3
580	Association Between Neuropsychiatric Symptoms and Functional Change in Older Non-Demented Adults: Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2020, 78, 911-917.	1.2	3
581	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. Neurobiology of Aging, 2020, 92, 135-140.	1.5	3
582	Brain amyloid, cortical thickness, and changes in activities of daily living. Annals of Clinical and Translational Neurology, 2020, 7, 474-485.	1.7	3
583	CSF dynamics as a predictor of cognitive progression. NeuroImage, 2021, 232, 117899.	2.1	3
584	Chronic Kidney Disease Associated with Worsening White Matter Disease and Ventricular Enlargement. Journal of Alzheimer's Disease, 2021, 83, 1729-1740.	1.2	3
585	Young-Onset Dementiaâ€”New Insights for an Underappreciated Problem. JAMA Neurology, 2021, 78, 1055.	4.5	3
586	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. NeuroImage: Clinical, 2022, 34, 102954.	1.4	3
587	Association of Performance on the Financial Capacity Instrumentâ€“Short Form With Brain Amyloid Load and Cortical Thickness in Older Adults. Neurology: Clinical Practice, 2022, 12, 113-124.	0.8	3
588	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimerâ€™s disease. Acta Neuropathologica, 2022, 143, 571-583.	3.9	3
589	Alzheimer's Disease and Other Dementias. , 2012, , 2274-2283.		2
590	Is dominantly inherited Alzheimer disease a clone of sporadic Alzheimer disease?. Neurology, 2015, 85, 750-751.	1.5	2
591	Beyond clinical syndromes in primary progressive aphasia. Neurology, 2017, 88, 2244-2245.	1.5	2
592	Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. Neurology: Genetics, 2017, 3, e201.	0.9	2
593	Extending Alzheimer disease biomarker studies into the Hispanic community. Neurology, 2020, 95, 665-666.	1.5	2
594	Preoperative cognitive impairment associated with oversedation during recovery from anesthesia. Journal of Anesthesia, 2020, 34, 390-396.	0.7	2

#	Article	IF	Citations
595	The quest for dementia prevention does not include an aspirin a day. Neurology, 2020, 95, 105-106.	1.5	2
596	Therapeutic Targets for Alzheimerâ€™s Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report. journal of prevention of Alzheimer's disease, The, 2022, 9, 231-235.	1.5	2
597	Polygenic Scores of Alzheimerâ€™s Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden. Journal of Alzheimer's Disease, 2022, 88, 1615-1625.	1.2	2
598	Commentary: â€œTreatment of hypertension and prevention of dementiaâ€•by Oliver Hanon and FranÃ§oise Forette. , 2005, 1, 41-42.		1
599	MRS in Early and Presymptomatic Carriers of a Novel Octapeptide Repeat Insertion in the Prion Protein Gene. Journal of Neuroimaging, 2013, 23, 409-413.	1.0	1
600	P2-079: ALZHEIMER'S AND VASCULAR DISEASE-SPECIFIC STRUCTURAL BRAIN CHANGES IN CHRONIC KIDNEY DISEASE PATIENTS. , 2014, 10, P498-P499.		1
601	Letter to the Editor re: Nexus of Cancer & Alzheimer's. Alzheimer's and Dementia, 2017, 13, 722-722.	0.4	1
602	P2â€•334: THE INFLUENCE OF BETAâ€•AMYLOID ON THE PROGRESSION OF PROGRESSIVE APRAXIA OF SPEECH. Alzheimer's and Dementia, 2018, 14, P810.	0.4	1
603	Incidence of Convexal Subarachnoid Hemorrhage in the Elderly: The Mayo Clinic Study of Aging. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 104451.	0.7	1
604	Gait Speed and Instrumental Activities of Daily Living in Older Adults After Hospitalization: A Longitudinal Population-Based Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, e272-e280.	1.7	1
605	Cognitive Heterogeneity in Alzheimer Clinical Trials. Neurology, 2021, 96, 1017-1018.	1.5	1
606	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. , 2011, 7, 263.		1
607	Associations between cerebrospinal fluid total phosphatidylcholines, neurodegeneration, cognitive decline, and risk of mild cognitive impairment in the Mayo Clinic Study of Aging. Neurobiology of Aging, 2020, 93, 52-54.	1.5	1
608	Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual. Journal of Alzheimer's Disease, 2021, , 1-6.	1.2	1
609	White matter changes in empirically derived incident MCI subtypes in the Mayo Clinic Study of Aging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12269.	1.2	1
610	Acute Strychnineâ€•Induced Seizures in Cats:A Golgi Study. Epilepsia, 1975, 16, 791-792.	2.6	0
611	Tacrine Treatment and Nursing Home Placement: Application of the Cox Proportional Hazards Model With Time-Dependent Covariates. Drug Information Journal, 1998, 32, 729-735.	0.5	0
612	Continuing the Tradition of Neuroanatomic Excellence. Journal of the International Neuropsychological Society, 2005, 11, 117-118.	1.2	0

#	Article	IF	Citations
613	Response to Letter from Dr. William Hazzard. Journal of the American Geriatrics Society, 2009, 57, 1317-1317.	1.3	0
614	F1-02-01: Mayo Clinic Study of Aging. , 2010, 6, S62-S62.		0
615	F4-03-03: Interpretation of delayed start trial data: Implications for researchers, clinicians, and patients. , 2015, 11, P262-P263.		0
616	Two Authors Reply. American Journal of Epidemiology, 2015, 181, 292-293.	1.6	0
617	FTS3â€01â€02: Epidemiology of Vascular Related Risk Factors for Dementia. Alzheimer's and Dementia, 2016, 12, P276.	0.4	0
618	O2â€08â€01: Av1451 Pet Imaging in the Spectrum of Alzheimer's Disease from Clinically Normal to Dementia. Alzheimer's and Dementia, 2016, 12, P243.	0.4	0
619	Behavioral Variant Frontotemporal Dementia. JAMA Neurology, 2016, 73, 1051.	4.5	0
620	[P4â€“015]: INTERNATIONAL SCIENTIFIC, ETHICAL AND REGULATORY REVIEW FOR ALZHEIMER'S CLINICAL TRIALS. Alzheimer's and Dementia, 2017, 13, P1259.	0.4	0
621	[O1â€“09â€“02]: RELATIONSHIPS OF VERY SMALL, INFARCTâ€LIKE LESIONS WITH 20â€YEAR COGNITIVE DECLINE: THE ARIC STUDY. Alzheimer's and Dementia, 2017, 13, P211.	0.4	0
622	[O1â€“12â€“05]: CONTINUOUS MEASURES OF Î²â€AMYLOIDOSIS AND CORTICAL THICKNESS IN RELATION TO COGNITIVE DECLINE IN COGNITIVELY NORMAL INDIVIDUALS: A POPULATIONâ€BASED STUDY. Alzheimer's and Dementia, 2017, 13, P223.	0.4	0
623	[O2â€“12â€“04]: EFFECTS OF CEREBROVASCULAR INFARCT BURDEN ON COGNITIVE DECLINE IN THE PRESENCE OF DEMENTIA AND DEATH: ACCOUNTING FOR POTENTIALLY INFORMATIVE DROPOUT USING COMPETING RISK SHARED PARAMETER MODELS: THE ARIC STUDY. Alzheimer's and Dementia, 2017, 13, P586.	0.4	0
624	Microinfarcts and blood pressure trajectories: response to Dr Niu et al.. Journal of Human Hypertension, 2018, 32, 385-385.	1.0	0
625	O1â€03â€05: ENTORHINAL CORTEX TAU PET, CORTICAL THICKNESS AND MEMORY PERFORMANCE IN COGNITIVELY UNIMPAIRED PERSONS. Alzheimer's and Dementia, 2018, 14, P221.	0.4	0
626	Early-Phase Randomized Clinical Trialsâ€”Expectations vs Hard Reality. JAMA Neurology, 2019, 76, 15.	4.5	0
627	Scientific Advising and Reviewing: On strengthening the bond between the Alzheimer's Association and the scientific community. Alzheimer's and Dementia, 2020, 16, 1095-1098.	0.4	0
628	Medical Doctors and Dementia: A Longitudinal Study. Journal of the American Geriatrics Society, 2020, 68, 1250-1255.	1.3	0
629	The Principle Syndromes of Dementia. , 2004, , 1216-1233.		0
630	Abstract P237: Measuring Cognition in the Atherosclerosis Risk in Communities (ARIC) Study Cohort: An approach to Account for Informative Attrition. Circulation, 2015, 131, .	1.6	0

#	Article	IF	Citations
631	Association of Indication for Hospitalization With Subsequent Amyloid Positron Emission Tomography and Magnetic Resonance Imaging Biomarkers. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 304-313.	1.7	0
632	Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia. Neurology, 2022, , 10.1212/WNL.0000000000200582.	1.5	0
633	CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer disease. Nature Reviews Neurology, 0, , .	4.9	0
634	Hypertension and Racial Differences in Dementia Reveal a Strategy for Risk Reduction in All Races. American Journal of Hypertension, 0, , .	1.0	0